Shares of Biogen Inc. BIIB shed 2.06% to $160.85 Tuesday, on what proved to be an all-around mixed trading session for the ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

Palantir Technologies leads the list of a half dozen companies that could be added to the $26 trillion Nasdaq 100 index at ...

Box, Inc. (NYSE:BOX), the leading Intelligent Content Management (ICM) platform, today announced preliminary financial ...

On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...

TOKYO: Japan’s Nikkei share average edged down on Wednesday, with investors booking profit after two straight days of gains ...

The article summarizes current notable health news, including Biogen's Alzheimer's drug growth, mysterious disease in Congo, ...

A maker of drug-device combination products with a St. Louis-based unit undergoing a $100 million expansion has named an IT ...

The article summarizes recent developments in the health sector, including Biogen's Alzheimer's drug growth, Idaho's abortion ...

President-elect Donald Trump is proposing allowing companies to record their domestic research and development expense immediately instead of amortizing them over five years.

DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

Japan’s Nikkei share average edged down on Wednesday, with investors booking profit after two straight days of gains as they ...